Pharmafile Logo

News and Press Releases

OBN Invites Life Science Leaders to Celebrate 20 Years of BioTrinity

Featuring keynotes from: Steve Bates, Executive Chair at the Office for Life Sciences, Lawrence Tallon, CEO at the MHRA & Maria Koufali, Life Sciences Industry Director at the NIHR, click...

Category: Other, Pharmaceutical
Posted: March 3, 2026

OBN
info@obn.org.uk
Unit 6 Library Avenue, Harwell, Didcot, OX11 0SG, UK

Immuthera Announces Global Exclusive License from City of Hope for First-in-Class CD6/CTLA-4 CAR-Treg Platform for Autoimmune and Inflammatory Diseases

Global exclusivity for Type 1 Diabetes, Rheumatoid Arthritis, 8 Dermatological Autoimmune diseases, and 13 Neuroinflammatory Autoimmune diseases Six patients with Chronic Graft versus Host Disease treated to-date with a favorable...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: January 12, 2026

Immuthera
office@immuthera.bio

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer

Series A led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments 8 October 2025 -- New York, New York...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 8, 2025

Nilo Therapeutics
info@nilotx.com

Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease

RTX001 is the first engineered Regenerative Macrophage Therapy (RMT) to be evaluated in humans with advanced liver fibrosis First patient has successfully cleared safety period with no serious adverse events...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: September 3, 2025

Resolution Therapeutics
contact@resolution-tx.com
Centre for Regenerative Medicine, University of Edinburgh, 5 Little France Drive, Edinburgh, EH16 4UU

Kite’s CAR T-Cell Therapy Data Show Real-World Patient Benefit and Durable Response Across Difficult-to-Treat Blood Cancers

Largest Real-World (RW) Analyses of Yescarta® (Axicabtagene Ciloleucel) Show 74% Overall Survival (OS) at 12 Months in Second-Line Relapsed/Refractory Large B-cell Lymphoma (LBCL), Consistent with OS Reported in Pivotal ZUMA-7 Study,...

Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: June 12, 2025

Kite Pharma
2400 Broadway Santa Monica, CA 90404

Quidditas raises €2.62M to accelerate development of pioneering genome editing technology

Funding will enable company to expand research capacity and scale up unique genome editing technology designed to treat complex, rare diseases while also opening new avenues for protein bioproduction and...

Category: BioManufacturing, Drug Discovery, Other, Pharmaceutical
Posted: May 12, 2025

Quidditas Therapeutics
contact@quidditastherapeutics.com
23, rue des bourguignons 91310 MONTLHERY

CN Bio and Pharmaron establish long-term strategic partnership to develop OOC technologies on a global R&D platform

Partnership to validate and promote the application of CN Bio’s PhysioMimix technology, with future opportunities for novel application and assay development 24 April 2025 -- Cambridge, UK -- CN Bio,...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 24, 2025

CN-Bio
enquiries@cn-bio.com
30 Upper High Street, Thame, Oxfordshire, OX9 3EZ

Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients

Primary endpoint met, no drug-related serious adverse events Positive hematoma and edema volume evolution Recruitment stopped early due to positive exploratory and efficacy outcomes Preparations underway to initiate Phase 2b...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 24, 2025

Bioxodes
info@bioxodes.com
Parc d'activités Aéropole Rue Santos-Dumont, 1 6041 Gosselies, Belgique

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

23 April 2025 -- Ingelheim, Germany and Amsterdam, the Netherlands -- Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025

Boehringer Ingelheim
Binger Strasse 173 55216 Ingelheim am Rhein

Pistoia Alliance Launches Initiative to Assess Sustainability of Digital vs. Traditional Clinical Trial Approaches

New initiative will collect pharma and CRO data to refine industry carbon measurement of technologies like remote monitoring and eConsent, informing more sustainable trial design 20 March 2025, Massachusetts, US...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025

The Pistoia Alliance
info@pistoiaalliance.org
401 Edgewater Pl, Wakefield, Massachusetts, US

Domain Therapeutics Discloses DT-9046 as a Groundbreaking Oral Drug Candidate for Inflammatory Diseases

DT-9046 is a highly differentiated first-in-class biased negative allosteric modulator of PAR2 with game changing potential across multiple inflammatory diseases Unique mechanism of action with potential to directly impact inflammation,...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025

Domain Therapeutics
contact@domaintherapeutics.com
PARC D'INNOVATION 220 Boulevard Gonthier D'Andernach 67400 Strasbourg - Illkirch - France

Innovaderm Research Rebrands as Indero, a dual-focus CRO 

7 March 2025 -- Quebec, Canada -- Innovaderm, a leading clinical research organization (CRO), is excited to reveal a major rebranding to Indero, with immediate effect. The new brand identity...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 7, 2025

Indero
3530 Saint-Laurent boulevard, Suite 300 Montreal, QC, H2X 2V1, Canada

Bioxodes obtains Orphan Drug Designation for hemorrhagic stroke therapeutic candidate in US and Europe

FDA, EMA grant BIOX-101 ODD status to treat intracerebral hemorrhagic stroke (ICH) ODD status may expedite drug candidate development and approvals BIOX-101 interim Phase 2a data in ICH imminent. 5...

Category: Drug Discovery, Other, Pharmaceutical
Posted: March 5, 2025

Bioxodes
info@bioxodes.com
Parc d'activités Aéropole Rue Santos-Dumont, 1 6041 Gosselies, Belgique

Kite Presents New Data on Patient Outcomes with CAR T-Cell Therapy at the 7th European CAR T-Cell Meeting, 6-8 February, Strasbourg, France

6 February 2025 -- Stockley Park, UK -- Kite, a Gilead Company, will share four posters that add to the growing body of evidence to support the clinical use of...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 6, 2025

Kite Pharma
2400 Broadway Santa Monica, CA 90404

Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications

Cognizant will provide AI-driven solutions to enhance customer service, employee engagement, and business value 30 January 2025 -- New Jersey, US -- Cognizant has announced an expansion of its longstanding relationship...

Category: Biotechnology, Drug Discovery, Logistics, Other, Pharmaceutical
Posted: January 30, 2025

Cognizant
inquiry@cognizant.com
Office Cognizant Technology Solutions World Headquarters Glenpointe Centre West 500 Frank W Burr Blvd Teaneck 07666 NJ